Aerpio Pharmaceuticals has completed enrollment in its phase 2 razuprotafib trial for patients with elevated IOP associated with open-angle glaucoma or ocular hypertension, according to a press release.
The double-masked, placebo-controlled trial of a topical ocular formulation of razuprotafib will evaluate safety and efficacy in about 195 patients over a 28-day period after a 28-day washout period.
Patients will receive latanoprost ophthalmic solution 0.005% at baseline before being randomly assigned into one of three arms of adjunctive therapy: placebo, 40 mg/mL razuprotafib once daily or 40
Uncategorized